| docetaxel oral/ritonavir (ModraDoc006/r) / Modra Pharma |
NCT01173913: Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir |
|
|
| Completed | 1 | 57 | Europe | ModraDoc001 10mg capsules, ModraDoc003 10mg tablets and ModraDoc004 10/50 mg, ModraDoc006 10 mg tablet | The Netherlands Cancer Institute | Cancer | 10/16 | 01/17 | | |
| Withdrawn | 1 | 0 | Europe | ModraDoc006/r, oral docetaxel formulation | Modra Pharmaceuticals | Solid Tumor, Adult | 04/18 | 06/18 | | |
NCT03147378: Food Effect Study of ModraDoc006 in Combination With Ritonavir |
|
|
| Completed | 1 | 18 | Europe | ModraDoc006/r, oral docetaxel formulation | Modra Pharmaceuticals, The Netherlands Cancer Institute | Solid Tumor, Adult | 04/18 | 04/18 | | |
| Completed | 1 | 17 | Europe | ModraDoc006/r, oral docetaxel formulation | Modra Pharmaceuticals | Advanced Solid Tumours | 05/18 | 05/19 | | |
NCT03066154: Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer |
|
|
| Terminated | 1 | 24 | Europe | oral docetaxel (ModraDoc/r), ModraDoc006/ritonavir, androgen deprivation therapy, hormonal therapy, high-dose intensity-modulated radiation therapy, radiotherapy | The Netherlands Cancer Institute | Prostatic Neoplasms | 02/22 | 08/22 | | |
| Completed | 1 | 23 | Europe | ModraDoc006/r, oral docetaxel formulation | Modra Pharmaceuticals, The Netherlands Cancer Institute | Castration-resistant Prostate Cancer | 09/19 | 09/19 | | |
NCT05084456: Oral Docetaxel in Patients With Normal or Impaired Liver Function |
|
|
| Withdrawn | 1 | 0 | Europe | ModraDoc006/r, Oral docetaxel formulation | Modra Pharmaceuticals | Solid Tumor, Adult, Impaired Liver Function | 02/20 | 04/20 | | |
